tradingkey.logo
tradingkey.logo
검색

Alkermes Plc

ALKS
관심 목록에 추가
55.080USD
0.0000.00%
종가 06/26, 16:00ET시세는 15분 지연됩니다
9.09B시가총액
59.24P/E TTM

자세한 내용은 Alkermes Plc 회사

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plc 정보

종목 코드 ALKS
회사 이름Alkermes Plc
상장일Jul 16, 1991
CEOPops (Richard F)
직원 수1800
유형Ordinary Share
회계 연도 종료Jul 16
주소Connaught House
도시DUBLIN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Ireland
우편 번호D04 C5Y6
전화35317728000
웹사이트https://www.alkermes.com/
종목 코드 ALKS
상장일Jul 16, 1991
CEOPops (Richard F)

Alkermes Plc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
229.52K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
77.39K
-5.17%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
25.68K
-7.79%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
18.22K
+25.61%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Mr. C. Todd Nichols
Mr. C. Todd Nichols
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
229.52K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
77.39K
-5.17%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%

자주 묻는 질문

Alkermes Plc의 상위 5대 주주는 누구인가요?

Alkermes Plc의 상위 5대 주주는 다음과 같습니다: Mr. Richard F. Pops

Alkermes Plc(ALKS)의 주식을 보유한 기관은 몇 개입니까?

2026Q1 기준으로, Alkermes Plc의 주식을 보유한 기관은 총 783곳이며, 이들이 보유한 주식의 총 가치는 약 182.39M로 전체 발행 주식의 109.43%를 차지합니다. 이는 2025Q4 대비 -11997400.00 증가한 수치입니다.

Alkermes Plc의 최대 수익원은 무엇인가요?

2026Q1 기준, Alkermes Plc의 VIVITROL 부문이 가장 높은 매출을 기록했으며, 금액은 467.91M로 전체 매출의 31.70%를 차지했습니다.
KeyAI